| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 7.337 | 13.976 | 17.759 | 17.459 | 17.326 | 16.965 | 15.902 | 13.383 | 14.556 | 14.474 |
| Total Income - EUR | 7.204 | 14.007 | 17.759 | 17.459 | 17.326 | 16.965 | 15.902 | 13.383 | 14.556 | 14.474 |
| Total Expenses - EUR | 8.399 | 4.543 | 4.330 | 4.170 | 4.274 | 5.232 | 4.547 | 5.474 | 11.752 | 8.490 |
| Gross Profit/Loss - EUR | -1.196 | 9.464 | 13.429 | 13.289 | 13.051 | 11.732 | 11.355 | 7.909 | 2.804 | 5.984 |
| Net Profit/Loss - EUR | -1.773 | 9.044 | 12.896 | 12.765 | 12.533 | 11.249 | 10.878 | 7.611 | 2.661 | 5.004 |
| Employees | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Total Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 43.411 | 41.305 | 39.001 | 36.709 | 34.453 | 32.283 | 30.085 | 28.691 | 27.121 | 25.495 |
| Current Assets | 3.335 | 2.936 | 1.760 | 2.046 | 5.626 | 13.024 | 12.170 | 2.979 | 2.006 | 2.714 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 559 | 358 | 381 | 393 | 364 | 1.609 | 1.030 | 806 | 431 | 343 |
| Cash | 2.776 | 2.578 | 1.379 | 1.653 | 5.262 | 11.415 | 11.141 | 2.173 | 1.575 | 2.371 |
| Shareholders Funds | 27.070 | 35.838 | 35.559 | 35.012 | 34.349 | 44.947 | 32.980 | 30.351 | 25.400 | 27.616 |
| Social Capital | 16.873 | 16.701 | 16.418 | 16.117 | 15.805 | 15.505 | 15.161 | 15.208 | 15.162 | 15.077 |
| Debts | 19.675 | 8.403 | 5.202 | 3.743 | 5.730 | 360 | 9.275 | 1.318 | 3.727 | 594 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
6820
|
|||||||||
Comments - Total Pharm Srl